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Butyrylcholinesterase 
and Acetylcholinesterase 
polymorphisms in Multiple Sclerosis 
patients: implication in peripheral 
inflammation
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Multiple Sclerosis (MS) is an autoimmune disease, having not fully understood aetiology, and both 
genetic and environmental factors contribute to the pathogenesis of the disease. The cholinergic 
system has been indicated as a mediator of neuro-immune interactions, as well as an internal regulator 
of immune responses. The aim of the present research was to assess the associations between BChE 
and AChE genetic variations and serum cholinergic and inflammatory profiles in 102 Relapsing 
Remitting-MS patients and 117 healthy controls. An increased frequency of the BChE K-allele in MS 
patients as compared to controls was found. In addition, data showed that patients had higher BChE 
enzymatic activity, which is increased by the presence of the polymorphic allele and reduced amounts 
of circulating ACh. AChE polymorphism was significantly associated to reduced activity in both patients 
and controls. We propose that serum BChE and AChE activity may be used as a secondary markers 
to assess the role of non-neuronal cholinergic system in regulating peripheral inflammation via ACh 
regulation. This pilot study shed light on the role of the non-neuronal cholinergic system in immune 
cells to better understand MS pathogenesis. The cross-talk between the periphery and the CNS could 
have a new undescribed crucial role for MS, regarded as a systemic disease.
Multiple Sclerosis (MS) is an autoimmune disease, and even if its aetiology is not yet fully understood, both 
genetic and environmental factors may contribute to the pathogenesis of the disease1–3. MS is considered a 
chronic autoimmune disease resulting in inflammation and demyelination of the central nervous system (CNS). 
Its inflammatory phase is characterized by the breaking down of immunological self-tolerance, by episodes of 
neurological disturbance (relapses) with complete or incomplete remissions, eventually leading to permanent 
impairment.
The cholinergic neurotransmission is involved in the regulation of the immune response during inflamma-
tion. Albeit other autoimmune or neurodegenerative processes could show a similar peripheral immune modi-
fication, and peripheral blood markers may not be specific for MS4, the blood remains the only readily available 
biological sample in patients and may help to identify new possible factors involved in the MS pathogenesis5. 
In addition, a crucial role for the cross-talk between the immune and nervous systems has been described. The 
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cholinergic system has been suggested as a mediator of neuro-immune interactions, as well as an internal regu-
lator of immune responses6,7.
Previous studies have demonstrated that acetylcholine (ACh) can modify immune responses. Thus, stim-
ulation of the α−7 nAChR (nicotinic cholinergic receptor) by neuronal or non-neuronal ACh, inhibits the 
release of pro-inflammatory mediators from immune cells by a cholinergic pathway called “anti-inflammatory 
non-neuronal cholinergic pathway”8,9. A comparable regulatory pathway has been described for microglia10.
Many studies have indicated that, besides neuronal ACh, non-neuronal cell types such as lymphocytes, mac-
rophages, dendritic cells, adipocytes, keratinocytes, endothelial cells, and epithelial cells, can produce and release 
ACh and express the ACh-hydrolysing enzymes acetyl-cholinesterase (AChE) and butyrylcholinesterase (BChE), 
the choline acetyltransferase (ChAT), and acetylcholine receptors of muscarinic and nicotinic type (AChRs)11–13. 
AChE and BChE share approximately 54% amino acid sequence identity. AChE rapidly hydrolyses ACh into 
acetic acid and choline at extremely fast turnover rates14. Alternative functions for AChE have been demon-
strated in neuronal and hematopoietic cells such as cell adhesion and proliferation of different types of neurons 
or regulation of proliferation and apoptosis of multipotent stem cells15–17. On the other hand, most tissues and 
body fluids contain another cholinesterase (ChE) named BChE. Despite the lower catalytic efficiency of BChE 
than AChE in hydrolysing ACh, BChE contributes to ACh homeostasis as judged by its role in AChE-null mice18. 
The catalytic action of AChE and BChE ensures rapid withdrawal of ACh, which, otherwise, may lead to cholin-
ergic over-activation. Butyrylcholinesterase (BChE) in normal brain and in Alzheimer’s disease (AD) regulates 
cognitive and behavioural functions19. However, the ability of BChE to hydrolyse ACh links this enzyme also to 
cholinergic neurotransmission and immune modulation. Changes in BChE activity in MS white matter lesions 
have been described20. Myelin, which is composed of a lipid bilayer membrane wraping the axons, is critical for 
neural signalling and transmission. BChE may be involved in MS in demyelination, due to its “lipolytic” activity, 
and in neuro-inflammation through acetylcholine hydrolysis. An increase in BChE activity results in reduced ace-
tylcholine levels and absent cholinergic anti-inflammatory responses, that may amplify systemic inflammation21.
However, it is difficult to conceive how hyperactivation of the two enzymes with high intrinsic 
ACh-hydrolysing capacity may have a meaningful pathophysiological impact on ACh levels. In order to balance 
the actions of highly abundant and efficient cholinesterases, the ACh-synthesizing machinery is however present 
in peripheral blood cells, whose function is to uphold steady-state equilibrium of ACh levels.
The genetic variations in BChE and AChE genes have been investigated in a number of low-grade systemic 
inflammation pathologies and in relation to the onset of Alzheimer’s disease22–26. In particular, two specific pol-
ymorphisms within these genes have been studied, namely rs1803274 for BChE and rs2571598 for AChE. These 
single nucleotide substitutions have been reported to reduce the enzymes activity of about 30–50% at least for 
BChE17,27. The BuChE rs1803274 is characterized by a G/A substitution inducing the Ala/Thr change at the codon 
539. This variation produces the so called K-allele which causes the reduction of 30%-60% of the ACh hydrolys-
ing activity28 and 30% of capacity of hydrolysing butyrylthiocholine29. The lowered hydrolytic activity of BChE 
K-allele predicts that BChE K-carriers would potentially sustain improved cholinergic activity. The presence of 
the K variant of BChE is controversially considered a risk factor for Alzheimer disease (AD). BChE K-carriers are 
refractory to cholinesterase inhibitor therapy, the current leading treatment for AD30.
The AChE rs2571598 is an intronic point mutation characterized by a C/T substitution which affects enzyme 
activity31. Discordant results have been reported about the association between AChE rs2571598 genotype and 
response of AD patients to AChE inhibitors treatment31,32.
We previously reported that serum BChE, AChE and ACh levels differs between MS and healty subjects33. 
The aim of the present research has been to analyse the associations between BChE and AChE genetic variations 
and altered serum cholinergic and inflammatory profiles. These data could be useful to shed in light the role of 
cholinergic system in modulating MS inflammation.
Results
AChE rs2571598 and BChE rs1803274 genotype and allele frequencies distribution in RR-MS 
patients and HD. Table 1 compares the genotype and allele frequencies of the AChE rs2571598 in RR-MS 
SNP Genotypes
RR-MS HD
OR (95% CI)n % n %
AChE rs2571598 102 117 1.73 (1.02–3.00) p < 0.05
No Carrier 33 32.3 53 45.3
Carrier 69 67.7 64 54.7
C/C 33 32.3 53 45.3 p = 0.068
C/T 54 52.9 44 37.6
T/T 15 14.8 20 17.1
Allele frequencies C 120 58.8 150 64.1 p = 0.301
T 84 41.2 84 35.9
HWE (p-value) χ
2 = 0.49; 
p = 0.5*
χ2 = 2.55; 
p = 0.1*
Table 1. AChE rs2571598 genotype and Allele Frequencies in RR-MS patients and HD subjects.
www.nature.com/scientificreports/
3ScIentIfIc REPORTS |  (2018) 8:1319  | DOI:10.1038/s41598-018-19701-7
patients versus HD controls. Genotype frequencies is according to the Hardy-Weinberg equilibrium, and no sta-
tistical significant differences were found in either genotype or allele frequencies distributions.
However, carrying C/T or T/T genotypes were more frequent in RR-MS patients than in HD controls (67.7% 
vs 54.7%; p < 0.05). The crude OR was 1.73 (95% CI: 1.02–3.00).
Similarly, when comparing the genotype and allele frequencies of the BChE rs1803274 (the so called 
K-variant) in RR-MS patients versus HD controls, the genotype frequencies is according to the Hardy-Weinberg 
equilibrium, and no statistical significant differences were found in either genotype or allele frequencies distri-
butions. Carrying G/A or A/A genotypes were more frequent in RR-MS patients than in HD control (49.0% vs 
35.9%; p < 0.05). The crude OR was 1.72 (95% CI: 1.01–2.95), (Table 2).
Peripheral cholinergic profiles in BChE K-carrier and no-carrier RR-MS patients and HD sub-
jects. Accordingly with our previous data34, BChE activity in serum was different between RR-MS patients 
and HD subjects, being higher in patients than in control (2510.2 ± 227.4 vs 2234.5 ± 192.9; p < 0.001).
In K-carriers HD groups we observed a reduction of serum BChE activity, while in K-carriers RR-MS patients 
an increase of serum BChE activity was detected (Fig. 1). Table 3 shows that in HD, BChE activity was about 
SNP Genotypes
RR-MS HD
OR (95% CI)n % n %
BChE rs1803274 102 117 1.72 (1.01–2.95) p < 0.05
No Carrier 52 51.0 75 64.1
Carrier 50 49.0 42 35.9
G/G 52 51.0 75 64.1 p = 0.142
G/A 42 41.2 36 30.8
A/A 8 7.8 6 5.1
Allele frequencies G 146 71.6 186 79.5 p = 0.069
A 58 28.4 48 20.5
HWE (p-value) χ
2 = 0.02 
p = 0.9* χ
2 = 0.2 p = 0.6*
Table 2. BChE rs1803274 genotype and Allele Frequencies in RR-MS patients and HD subjects.
Figure 1. Levels of BChE enzymatic activity in RR-MS patients and HD stratified for presence of BChE 
K-polymorphism (carrier) and no-carrier for both polymorphism. (Mean ± Standard error; SE).
BChE rs1803274
RR-MS HD ANOVA p-value
Carrier No Carrier Carrier No Carrier
RR-MS vs 
HD
Carrier vs 
No carrier Interaction
BChE (mU/mL) 2757.3 ± 262.6 2418.6 ± 184.1 2121.3 ± 162.2 2348.1 ± 290.7 0.035 0.365 0.089
AChE (mU/mL) 1066.5 ± 843.8 858.2 ± 189.1 420.6 ± 41.6 567.2 ± 145.7 0.012 0.871 0.571
ACh (pmol/mL) 67.7 ± 56.7 98.1 ± 60.1 681.7 ± 418.8 514.0 ± 144.4 <0.001 0.623 0.397
Table 3. Levels of cholinergic markers in BChE K-carrier and no-carrier RR-MS patients and HD subjects. 
Data are expressed as mean and standard deviation.
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10% lower in K-carriers than in no-carriers. In addition, in the HD group, K-carriers had higher levels of ACh 
(about + 25%), and reduced AChE levels that may be responsible for higher ACh levels observed.
In HD the ratio BChE/ACh was respectively 3.1 in K-carriers, and 4.9 in non-carriers. In these subjects, 
the ratio AChE/ACh was lower, while the ratio BChE/AChE was not significantly different, when compared to 
non-carrier subjects. Thus, our observation suggest that in HD, the BChE-K allele might have an impact on the 
AChE activity and ACh levels.
In RR-MS patients BChE activity was about 14% higher in K-carriers than in non-carriers, while AChE activ-
ity is higher in K-carriers than in non-carriers. The K-carrier RR-MS patients had lower levels of ACh and the 
ratio BChE/ACh was 32.5 and 23.7 in K-carrier and non-carrier patients, respectively.
The ratio BChE/ACh may be indicative of the extra-synaptic ACh equilibrium status, since the higher BChE/
ACh ratio observed in K-carriers compared to non-carrier RR-MS patients plausibly will lead to less degradative 
activity of BChE, which is however higher compared to HD K-carrier subjects (Table 4).
BChE genotype and cytokine levels. Since BChE K-variant is associated with reduced ACh-hydrolysing 
capacity of the enzyme, and considering the increasing evidence of the immune-regulatory role of ACh, we 
investigated if genetic heterogeneity in BChE may affect pro-inflammatory cytokines. Particularly, we investi-
gated whether in RR-MS patients and HD subjects, the K allele was related to serum levels of pro-inflammatory 
cytokines TNFα, IL-17, IL-18 and IL-12/p40.
In HD K-carriers, in accord with lower BChE-hydrolysing capacity and higher ACh levels, we observed lower 
TNFα, IL-17, IL-18, and IL-12p40 levels when compared to non-carriers HD (Table 5). Thus in HD, BChE geno-
type exerts regulatory effects on pro-inflammatory cytokines, possibly via regulation of extracellular ACh levels. 
This finding lends to further support the immune-regulatory function of ACh, that may act as possible negative 
regulator of inflammation caused by the aberrant T-cell activation.
In RR-MS K-carrier patients we observed not significantly differences in inflammatory cytokine levels, prob-
ably dependent on the lower ACh levels, as a result of higher levels of both ChE enzymes.
Thus, while BChE K-genotype in HD donors causes the reduction of BChE hydrolysing activity with expected 
increase of ACh levels and reduced inflammatory environment in the serum, in RR-MS K-carriers the increase of 
BChE and ACh was associated to an increase of inflammatory cytokines levels.
Peripheral cholinergic profiles in AChE rs2571598 genotype carrier and non-carrier RR-MS 
patients and HD subjects. AChE activity in serum is different between RR-SM patients and HD, showing 
higher activity in patients (793.5 ± 223.5 vs 561.3 ± 100.2; p < 0.001). In both RR-MS patient and HD groups we 
observed a reduction of AChE activity in serum of AChE rs2571598 genotype carriers (Fig. 2).
In HD carriers of the AChE rs2571598 genotype, ACh levels were 40% higher than in non-carriers. In RR-MS 
carriers of the AChE rs2571598 genotype, AChE activity was about 30% lower, while ACh levels were significantly 
higher, than in non-carriers (p = 0.047). The lower levels of ACh, in non-carrier RR-MS patients, probably are 
modulated by higher AChE and BChE hydrolysing activity (Table 6).
In HD rs2571598 carriers the ratio AChE/ACh is 1.1 and 1.5 in carriers and non-carriers HD, respectively. In 
RR-MS patients the AChE/ACh ratio is 3.1 and 7.7 in carriers and non-carriers, respectively (Table 7).
AChE genotype and cytokine levels. In HD rs2571598 carriers, in accord with higher ACh levels, 
we observed lower TNFα, IL-17, IL-18 and IL-12/p40 levels compared to non-carriers. In addition, RR-MS 
rs2571598 carriers show lower levels of inflammatory cytokine TNFα and IL-17, and no differences for IL-18 
BChE rs1803274
RR-MS HD
Carrier No Carrier Carrier No Carrier
AChE/ACh 15.8 ± 8.2 7.8 ± 3.0 0.7 ± 2.7 1.2 ± 0.8
BChE/ACh 32.5 ± 16.2 23.7 ± 10.9 3.1 ± 1.5 4.9 ± 2.9
BChE/AChE 2.7 ± 0.9 3.5 ± 0.3 5.0 ± 0.2 4.2 ± 0.3
AChE + BChE/ACh 43.7 ± 27.1 24.2 ± 15.7 3.9 ± 2.7 5.8 ± 2.7
Table 4. Ratio between cholinergic enzymes activity and ACh levels BChE K-carrier and no-carrier RR-MS 
patients and HD subjects. Data are expressed as mean and standard error.
BChE rs1803274
RR-MS HD ANOVA p-value
Carrier No Carrier Carrier No Carrier
RR-MS vs 
HD
Carrier vs no 
carrier Interaction
TNFα (pg/mL) 19.4 ± 2.1 16.9 ± 5.6 2.4 ± 0.9 4.8 ± 3.1 <0.001 0.065 0.564
IL-17 (pg/mL) 41.8 ± 13.9 40.4 ± 22.0 10.4 ± 5.2 16.8 ± 3.8 0.027 0.467 0.768
IL-18 (pg/mL) 357.0 ± 63.5 286.7 ± 41.8 168.2 ± 17.1 205.1 ± 22.0 <0.001 0.787 0.642
IL12/p40 (pg/mL) 329.3 ± 41.2 274.4 ± 15.9 76.7 ± 43.2 109.6 ± 36.9 <0.001 0.678 0.498
Table 5. Levels of cytokines in serum in BChE K-carrier and no-carrier RR-MS patients and HD subjects. Data 
are expressed as mean and standard deviation.
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and IL-12/p40 levels. Thus, AChE genotype exerts regulatory effects on pro-inflammatory cytokines, possibly via 
regulation of ACh levels in both HD and RR-MS. In RR-MS patients carrying rs2571598 both AChE and BChE 
hydrolysing activities were reduced, parallel to higher ACh levels. In HD rs2571598 carriers, a not significantly 
reduction of BChE and AChE activity was responsible of a significant increase of ACh levels that may drive the 
observed reduction of inflammatory cytokines (Table 8).
Figure 2. Levels of AChE enzymatic activity in in RR-MS patients and HD stratified for presence of AChE 
rs2571598 (carrier) and no-carrier for both polymorphism. (Mean ± Standard error; SE).
AChE rs2571598
RR-MS HD ANOVA p-value
Carrier No Carrier Carrier No Carrier
RR-MS 
vs HD
Carrier vs 
no carrier Interaction
BChE (mU/mL) 2325.9 ± 998.1 2418.6 ± 184.1 2271.7 ± 252.9 2348.1 ± 290.7 0.227 0.654 0.943
AChE (mU/mL) 596.8 ± 543.9 858.2 ± 189.1 556.0 ± 87.2 567.2 ± 145.7 0.015 0.763 0.781
ACh (pmole/mL) 237.1 ± 354.2 98.1 ± 60.1 701.2 ± 345.7 514.0 ± 144.4 0.004 0.047 0.652
Table 6. Levels of cholinergic markers in AChE rs2571598 genotype carrier and no-carrier RR-MS patients and 
HD subjects. Data are expressed as mean and standard deviation.
AChE 
rs2571598
RR-MS HD
Carrier No Carrier Carrier
No 
Carrier
AChE/ACh 3.1 ± 3.7 7.7 ± 2.4 1.1 ± 1.7 1.5 ± 0.8
BChE/ACh 9.9 ± 8.7 25.2 ± 14.1 3.5 ± 2.2 4.5 ± 3.8
BChE/AChE 3.8 ± 0.5 3.1 ± 0.8 4.1 ± 0.2 4.2 ± 0.1
AChE + BChE/
ACh 13.1 ± 8.7 32.8 ± 12.7 4.8 ± 0.7 5.5 ± 3.7
Table 7. Ratio between cholinergic enzymes activity and ACh levels in AChE rs2571598 genotype RR-MS 
patients and HD subjects. Data are expressed as mean and standard error.
AChE rs2571598
RR-MS HD ANOVA p-value
Carrier No Carrier Carrier No Carrier
RR-MS vs 
HD
Carrier vs no 
carrier Interaction
TNFα (pg/mL) 14.3 ± 3.6 16.9 ± 5.6 1.6 ± 1.2 4.8 ± 3.1 <0.001 0.051 0.617
IL-17 (pg/mL) 37.2 ± 18.2 40.4 ± 22.0 9.7 ± 4.8 16.8 ± 3.8 0.009 0.047 0.987
IL-18 (pg/mL) 283.6 ± 52.0 286.7 ± 41.8 168.9 ± 12.9 205.1 ± 22.0 <0.001 0.465 0.632
IL-12/p40(pg/mL) 276.4 ± 33.2 274.4 ± 15.9 80.4 ± 47.6 109.6 ± 36.9 <0.001 0.871 0.596
Table 8. Cytokines levels in AChE rs2571598 genotype carrier and no-carrier RR-MS patients and HD subjects. 
Data are expressed as mean and standard deviation.
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Discussion
Increasing evidences suggested a role for the cholinergic system in the regulation of the inflammatory pathway. 
One of the consequences of changes in the ACh equilibrium concerns the immune-regulatory function of cho-
linergic signalling through the action of ACh on cells involved in native and adoptive immune responses33–35. 
Neuroinflammation in MS brain, initially described as an accumulation of leukocytes, is based upon and is regu-
lated by bidirectional communication pathways involving cytokines that connect the CNS and immune system. 
Several studies have reported high levels of inflammatory cytokines in MS and have hypothesized the influences 
of circulating cholinesterases and ACh levels in the serum34,36,37. Thus, we have investigated, for the first time, 
the relationships between the over-production of circulating cholinesterases, the genetic variations of BChE and 
AChE genes and the levels of circulating cytokines in MS patients.
Our results showed that RR-MS patients have higher serum levels of BChE and AChE compared to HD sub-
jects, and this could explain the reduced amount of circulating ACh observed in patients. We investigated if lower 
ACh concentration observed in RR-MS compared to HD may be related to the ability to regulate the extracellular 
ACh, when needed, or to the variation of AChE or BChE activity.
Data showed that AChE rs2571598 and BChE rs1803274 genotype were more frequent in RR-MS patients 
than in HD control. Results highlighted that in RR-MS patients carrying the K-allele, higher BChE levels were 
observed, albeit it is in contrast with the reported role of this SNP in BChE gene, and that this over-load of circu-
lating BChE remove ACh, but not sufficiently to reduce efficiently levels of all examined cytokines. Probably, other 
mechanisms, such as increased transduction of BChE, microRNAs or other genetic factors acting in conjunction 
with BChE-K, could be involved in the balance of the BChE. The reduced peripheral cholinergic activity, detected 
in K-carrier HD subjects, may be responsible for the higher ACh levels and for reduction of pro-inflammatory 
cytokines analysed. The differential levels of ACh detected in K-carriers subjects seem to reflect a physiological 
adaptation to the ACh-hydrolysing status. Thus, as a relative index for the extracellular ACh equilibrium state, we 
calculated the ratio of AChE or BChE activity to ACh in the serum of MS K-carrier or no-carrier patients, com-
pared to age-matched controls. An higher BChE + AChE/ACh ratio should indicate a high ACh-hydrolysing sta-
tus and/or a low ACh-synthesizing status. We found that this ratio is higher in the BChE K-carriers RR-MS group 
than in non-carriers RR-MS group. In the same group we observed higher levels of the inflammatory cytokines, 
related to reduced ACh levels. In HD group expressing BChE K-variant, the BChE + AChE/ACh ratio is lower 
than in non-carriers HD group. When comparing the BChE + AChE/ACh ratio in both RR-MS and HD BChE 
K-carriers, the ratio resulted higher in patients versus control, in accord with higher inflammatory cytokines 
levels. This observation strengthen the role of ACh in the control of inflammation21,36,38.
In addition our data showed that the BChE K-allele is associated with an increase of circulating AChE in 
RR-MS, confirming a close relation between the expression of BChE and that of AChE which has long been 
known39. HD show, as expected, increased levels of ACh when the serum levels of BChE and AChE are lower.
Albeit AChE rs2571598 genotype results at least associated with reduced serum AChE levels, more evident in 
RR-MS patients. The single nucleotide substitution may alter hydrolizing properties, possible for misfolded con-
formation and formation of a unstable conformation23. We found that in both RR-MS patients and HD groups, 
ACh levels were higher in subjects carrying the polymorphic allele, while no significantly differences in BChE lev-
els were observed. This suggests that AChE rs2571598 genotype may be involved in the lower levels of cytokines 
detected in serum of AChE rs2571598 carrier subjects, accordingly to lower Ach degradation. This could indicate 
that AChE genotype may affects the production of inflammatory mediators via regulation of the extracellular 
levels of ACh. Taken together these data demonstrate that in RR-MS patients the pro-inflammatory immune 
responses through hydrolysis of acetylcholine could be related to alterations in ChE activity, depending on spe-
cific genetic endophenpotypes.
In conclusion, we confirmed that total plasma BChE and AChE activity are higher in RR-MS patients than 
in healthy controls, an increased frequency of the AChE rs2571598 and BChE rs1803274 in MS patients as com-
pared to controls was found, the plasma ChE activity is associated with ACh levels and with inflammatory status.
Cholinergic system modifications, observed in the periphery could reflect what happens in the CNS, being 
relevant for immune activation/inflammation, underlining that MS may be considered a systemic disease, where 
a cross-talk between the periphery and the CNS could have an undescribed crucial role. Furthermore, we propose 
that serum BChE and AChE activity may be used as a secondary markers to assess the role of non-neuronal cho-
linergic system in regulating peripheral inflammation via ACh regulation. However, studies on larger populations 
are needed to confirm the role of non-neuronal cholinergic system in immune cells to better understand MS 
aetiology and progression and to develop new disease-modifying therapies for MS, with ChE and ACh as targets.
Methods
Subjects. Relapsing Remitting-MS (RR-MS) patients were enrolled and followed at Department of 
Neuroscience of S. Camillo-Forlanini Hospital (Rome, Italy). The diagnosis of RR-MS was confirmed according 
to revised Mc Donald Diagnostic Criteria40 and RR-MS course was established by clinical parameters41 in agree-
ment with recent classification42. Enrolled patients haven’t been exposed to prior immunomodulatory therapies, 
such as interferon beta preparations, glatiramer acetate and monthly pulses of intravenously-administered sol-
umedrol; however, they were off these therapies for a minimum of 6 months before the blood collection.
Healthy donors (HD) were enrolled from the Transfusion Blood Bank Services of Chieti (Italy) and were 
frequency matched for age and gender. Mean age, mean disease duration and EDSS distribution are shown in 
Table 9. All subjects had not suffered, in the previous month, from inflammatory diseases that might be asso-
ciated with modulation of cytokines, and had not received corticosteroids or immunosuppressive drugs. All 
RR-MS patients and HD signed an informed consent. The study was approved by Ethical Committee of San 
Camillo-Formanini Hospital (prot. n 1457/2016).
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Determination of ACh levels, AChE and BChE Activity. ACh was measured by commercial fluori-
metric kit (Abcam, Cambridge, UK), using the Glomax Multi Detection System (Promega, Mi, Italy) at λ Ex/Em 
535/587 nm.
Cholinesterases activity were measured in sera of RR-MS patients and HD by Ellman assay43, using 1 mM final 
concentration of acetyl-thiocholine iodide as substrate. In order to evaluate the contribution of AChE and BChE 
to the total cholinesterase activity, 1.4 × 10−5 M BW284c51 or 1.4 × 10−5 M lysivane were respectively added as 
appropriate inhibitors, in the reaction mixture containing 0.33 mM DTNB (di-nitro-thiocyanobenzene) in 0.1 M 
phosphate buffer, pH 7. Enzyme activity was expressed as mU; 1 mU corresponding to 1 nmole of substrate 
hydrolysed/min at 30 °C.
Genotyping. Genomic DNA was extracted from whole blood using the NucleoSpin Tissue kit 
(Macherey-Nagel, Bethlehem, PA, USA). Genotyping was performed with being blind to case control status for 
the specific polymorphisms reported in Table 10. The amplification reaction conditions were as follows: denatur-
ation at 94 °C for 10 min followed by 30 cycles at 94 °C for 30 sec, 30 sec at the annealing temperature optimum for 
each pair of primers (Table 10), 72 °C for 30 sec, with a final elongation step at 72 °C for 10 min.
The specificity of the PCR amplified products was evaluated by 2% agarose gel electrophoresis. The gene pol-
ymorphisms were observed by direct sequencing on ABI 3130xl genetic analyzer (Applied Biosystems), on both 
strands.
Hardy-Weinberg equilibrium (HWE) deviations in the genotype frequency distributions were calculated 
using the χ square analysis. Hardy-Weinberg-equilibrium-calculator software was used to check for Haplotype 
association analysis (http://www.had2know.com/academics/hardy-weinberg-equilibrium-calculator-2-alleles.
html).
Cytokine measurements. ELISA assay was conducted with commercial kits (R&D System) according to 
the manufacturer’s instructions to quantify human cytokine levels in serum. The plates were read at 450 nm and 
the absorbance was converted in pg/ml, using calibration curves prepared with cytokine standards. The intra- and 
inter-assay reproducibility were > 90%.
Statistical analysis. The quantitative variables were summarized as mean and standard deviation (SD) or 
median and interquartile range (IQR), according to their distribution. Qualitative variables were summarized 
as frequency and percentage. A Shapiro-Wilk’s test was performed to evaluate the departures from normality 
distribution for each variable.
The difference in frequencies between patients and controls were assessed by a chi-square test or Fischer exact 
test when appropriate.
The association between AChE and BChE polymorphisms with SM was assessed by univariate logistic regres-
sion analyses. Logistic regression model was applied to estimate the adjusted Odds Ratio (OR) and relative 95% 
confidence intervals.
The analyses of relationship between genotypes and enzymes activity was performed excluding patients 
carrying both polymorphisms. Patients with only one polymorphism (carrier group) or without both variants 
(no-carrier group) were analysed. Two-way analysis of variance (ANOVA) was performed to test the effect of 
Variable
RR-MS 
(n = 102) HD (n = 117) p-value
Age (yr), mean ± SD 43.0 ± 8.7 47.8 ± 11.2 0.070
Gender, n(%) 0.930
 Female 71 (69.7) 80 (68.5)
 Male 31 (30.3) 37 (31.4)
EDSS, n(%) —
 <3 85 (83.2)
 ≥3 17 (16.8)
BOC, n(%) —
 Positive 78 (76.8)
 Negative 24 (23.2)
Duration of disease 
(yr), mean ± SD 9.7 ± 6.8 —
Table 9. Characteristics of RR-MS patients and HD subjects.
Polymorphism Primer Forward Primer Reverse
Annealing 
Temperature
BChE rs1803274 (G > A) ATTAGAGACCCACACAACTT ATATTTTACAGGAAATATTGATGAA 55
AChE rs2571598 (C > T) AGAGTCGGGGTCTTGTTATGT AAAGTGAGGAGGAGACGAGG 60
Table 10. Sequences of the primers for BChE rs1803274 and AChE rs2571598.
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different AChE and BChE genotypes (carrier or no-carrier), different group (RR-MS or HD) and their interaction 
on levels of BChE, AChE, ACh and cytokines with group as a fixed effect and genotype as a random effect.
The level of statistical significance was set at p < 0.05. Statistical analysis was performed using IBM® SPSS 
Statistics v 20.0 software (SPSS Inc, Chicago, Illinois, USA).
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